Company
OKYO Pharma Ltd (OKYO)
Standardized SEC financial data for OKYO Pharma Ltd — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0001849296 · NASDAQ · Biological Products, (No Diagnostic Substances).
Return on equity
84.8%
Income statement
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| R&D expense | $518K | $348K | $1.6M | $6.3M | $8.2M | $2.3M |
| Net income | -$1.5M | -$3.4M | -$5.4M | -$13.3M | -$16.8M | -$4.7M |
Standardized from OKYO Pharma Ltd's SEC filings — per-share figures split-adjusted. Full history via the API.
Balance sheet
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total assets | — | $7.1M | $4.3M | $5.2M | $1.5M | $3.7M |
| Total liabilities |
Get OKYO data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/OKYO/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/OKYO/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"